Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5734690 | 0.79 | MAPK1 (0.30) | — | |
| SCHEMBL21584135 | 0.70 | TDP1 (0.50) | CYP2D6SMN1; SMN2ALDH1A1 | |
| SCHEMBL4683154 | 0.68 | BRD4 (0.30) | BRD4 | |
| SCHEMBL4683151 | 0.68 | BRD4 (0.30) | BRD4 | |
| SCHEMBL47323 | 0.67 | — | — | |
| SCHEMBL13764866 | 0.66 | — | — | |
| SCHEMBL13764867 | 0.66 | — | — | |
| SCHEMBL13764865 | 0.66 | — | — | |
| SCHEMBL6553005 | 0.66 | — | — | |
| SCHEMBL13764868 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230014383-A1 | THREE FUSED RING DERIVATIVE-CONTAINING SALT OR CRYSTAL FORM AND PHARMACEUTICAL COMPOSITION THEREOF | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230014383-A1 | THREE FUSED RING DERIVATIVE-CONTAINING SALT OR CRYSTAL FORM AND PHARMACEUTICAL COMPOSITION THEREOF | AKT2, AKT3, PIK3R5 | BRD4 3163/4885CYP2C19 1346/4885CYP1A2 2046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.